DM5167

DM5167 is a **second-generation, selective PARP1 inhibitor** developed primarily for the treatment of **triple-negative breast cancer** (TNBC)[1][2][3][4][5][9]. It is distinguished by its **high selectivity for PARP1 over PARP2** (6.88-fold selectivity in enzymatic assays, 348-fold greater PARP trapping), minimizing hematological toxicity relative to earlier poly(ADP-ribose) polymerase (PARP) inhibitors[9]. Preclinical and early clinical data suggest DM5167 demonstrates effective **DNA trapping capability**, potent anti-tumor activity, and **superior brain permeability**, making it particularly promising for treating **brain metastases and brain cancers**, especially in patients with BRCA mutations or other homologous recombination deficiencies[1][2][3][7][9]. DM5167 is being developed by **DigmBio** (South Korea) in collaboration with manufacturing support from **BioDuro-Sundia**. The molecule is being investigated in phase 1 clinical trials, including in patient populations with BRCA mutant and HRD mutant metastatic brain tumors[2][6][7].